Treatment of hyperproliferative skin disorders with C18 to C26 a

Details Treatment of hyperproliferative skin disorders with C18 to C26 a Treatment of hyperproliferative skin disorders with C18 to C26 a

1997-11-25

1999-09-07

Cook, Rebecca

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

C-o-group doai

514863, A61K 31045

Patent

active

059488220

ABSTRACT:
A method for treating a benign or malignant hyperproliferative skin lesion, comprising topically administering a C18 to C26 aliphatic alcohol to the skin lesion in a pharmaceutically acceptable carrier.

REFERENCES:
patent: 3592930 (1971-07-01), Katz et al.
patent: 3863633 (1975-02-01), Ryde et al.
patent: 4186211 (1980-01-01), Debat
patent: 4670471 (1987-06-01), Clark
patent: 4874794 (1989-10-01), Katz
patent: 5070107 (1991-12-01), Katz
patent: 5071879 (1991-12-01), Katz
patent: 5166219 (1992-11-01), Katz
patent: 5194451 (1993-03-01), Katz
patent: 5534554 (1996-07-01), Katz et al.
Berkow, et al., Dermatologic Disorders, The 16th Merck Manual, Merck Research Lab, xp002064741 p. 2460 (1992).
D.H. Katz, et al., "Antiviral activity of 1-docosanol, an inhibitor of lipid-enveloped viruses including herpes simplex", Proc. Natl. Acad. Sci. USA 88:10825-10829 (1991).
L.E. Pope, et al., "Anti-herpes simlex virus activity of n-docosanol correlates with intracellular metabolic conversion of the drug", Jour. of Lipid Research 37:2167-2178 (1996).
Report of the Centers for Disease Control Task Force on Kaposi's Sarcoma and Opportunistic Infections, "Epidemiologic Aspects of the Current Outbreak of Kaposi's Sarcoma and Opportunistic Infections", The New England Jour. of Medicine pp. 248-252 (1982).

Affiliated with

Also associated with

Rating

Treatment of hyperproliferative skin disorders with C18 to C26 a does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Treatment of hyperproliferative skin disorders with C18 to C26 a, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of hyperproliferative skin disorders with C18 to C26 a will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1805025